ArticleNPJ breast cancer2024

CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape.

Nayan Chaudhary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.